Oramed Pharmaceuticals Inc (ORMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($238.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oramed Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Oramed Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oramed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Oramed Pharmaceuticals Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tigbur - Temporary Professional Personnel Ltd
TA:TIGBUR
|
-0.021x |
|
Asia Plus Group Holdings PCL
BK:ASP
|
0.253x |
|
Exel Industries
PA:EXE
|
-0.052x |
|
Leapfrog Acquisition Corporation Class A Ordinary Shares
NASDAQ:LFAC
|
-0.001x |
|
Lavras Gold Corp
V:LGC
|
-0.018x |
|
Stratus Properties Inc
NASDAQ:STRS
|
-0.045x |
|
K2 Gold Corporation
V:KTO
|
-0.009x |
|
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
|
0.063x |
Annual Cash Flow Conversion Efficiency for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oramed Pharmaceuticals Inc from 2005 to 2025. View current stock price of Oramed Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $199.74 Million | $-9.14 Million | -0.046x | +20.89% |
| 2024-12-31 | $145.35 Million | $-8.41 Million | -0.058x | +8.43% |
| 2023-12-31 | $162.89 Million | $-10.29 Million | -0.063x | +66.71% |
| 2022-12-31 | $151.16 Million | $-28.70 Million | -0.190x | -4.45% |
| 2021-12-31 | $116.52 Million | $-21.18 Million | -0.182x | +51.95% |
| 2020-12-31 | $32.88 Million | $-12.44 Million | -0.378x | +43.30% |
| 2019-12-31 | $19.39 Million | $-12.94 Million | -0.667x | -41.64% |
| 2018-12-31 | $31.11 Million | $-14.66 Million | -0.471x | -55.43% |
| 2017-12-31 | $19.24 Million | $-5.83 Million | -0.303x | -270.53% |
| 2016-12-31 | $26.19 Million | $4.66 Million | 0.178x | +189.22% |
| 2015-12-31 | $24.83 Million | $-4.95 Million | -0.199x | -1.82% |
| 2014-12-31 | $20.79 Million | $-4.07 Million | -0.196x | +53.15% |
| 2013-12-31 | $8.13 Million | $-3.40 Million | -0.418x | +31.45% |
| 2012-12-31 | $3.78 Million | $-2.30 Million | -0.609x | -36.17% |
| 2011-12-31 | $3.72 Million | $-1.67 Million | -0.447x | +73.81% |
| 2010-12-31 | $830.27K | $-1.42 Million | -1.708x | -108.25% |
| 2009-12-31 | $2.75 Million | $-2.25 Million | -0.820x | -105.12% |
| 2008-12-31 | $4.59 Million | $-1.84 Million | -0.400x | +66.42% |
| 2007-12-31 | $513.00K | $-611.00K | -1.191x | -242.52% |
| 2006-12-31 | $-432.72K | $-361.61K | 0.836x | -7.39% |
| 2005-12-31 | $-44.81K | $-40.44K | 0.902x | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more